SCHEMBL14726641

SCHEMBL14726641

CCOc1cc2c(Nc3cc(Cl)cc(Cl)c3)nc(-c3cccnc3)nc2cc1OC

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ABCG2 Q9UNQ0 7/20 0.56
▸ ABCB1 P08183 2/20 0.56
▸ MEN1 O00255 3/20 0.49
▸ USP2 O75604 3/20 0.49
▸ KMT2A Q03164 3/20 0.49
▸ EPHA2 P29317 2/20 0.48
▸ KDR P35968 2/20 0.48
▸ EPHB4 P54760 2/20 0.48
▸ FLT1 P17948 1/20 0.47
▸ KDM4E B2RXH2 3/20 0.47
▸ MAPT P10636 3/20 0.47
▸ CYP1A2 P05177 3/20 0.47
▸ CYP3A4 P08684 3/20 0.47
▸ NPSR1 Q6W5P4 2/20 0.47
▸ CYP2D6 P10635 2/20 0.47
▸ CYP2C9 P11712 2/20 0.47
▸ CYP2C19 P33261 2/20 0.47
▸ FBP1 P09467 1/20 0.46
▸ ALDH1A1 P00352 3/20 0.46
▸ LMNA P02545 3/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14474025 0.93 ABCG2 (0.63) ABCG2ABCB1MEN1USP2KMT2A
SCHEMBL14474855 0.89 EPHA2 (0.61) ABCG2ABCB1MEN1USP2KMT2A
SCHEMBL14474856 0.89 FBP1 (0.57) ABCG2ABCB1EPHA2KDREPHB4
SCHEMBL14474017 0.88 ABCG2 (0.58) ABCG2ABCB1MEN1USP2KMT2A
SCHEMBL14474839 0.87 ABCG2 (0.59) ABCG2ABCB1MEN1USP2KMT2A
SCHEMBL14474459 0.87 ABCG2 (0.56) ABCG2ABCB1MEN1USP2KMT2A
SCHEMBL14726069 0.84 ABCG2 (0.58) ABCG2ABCB1MEN1USP2KMT2A
SCHEMBL14474870 0.83 ABCG2 (0.64) ABCG2ABCB1MEN1KMT2AKDM4E
SCHEMBL14474417 0.82 EPHA2 (0.61) ABCG2ABCB1MEN1USP2KMT2A
SCHEMBL14726642 0.82 ABCG2 (0.57) ABCG2ABCB1MEN1USP2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9073890-B2 Therapeutic compounds and related methods of use OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2015-07-07 — — US disclosed
US-20130053341-A1 THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE OTSUKA PHARMACEUTICAL COMPANY (JP) 2013-02-28 — — US disclosed
US-20130053341-A1 THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE OTSUKA PHARMACEUTICAL COMPANY (JP) 2013-02-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130053341-A1 THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE PPP4C, PPP3CB, PTPRG ABCG2 2822/4885ABCB1 4758/4885MEN1 4770/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback